CSL stock: Evans and Partners cuts rating to Neutral
Published on 11/21/2026 at 10:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst downgrade shapes CSL outlook
- Evans and Partners moved its CSL recommendation to Neutral on November 16.
- The analyst firm set a price target of AUD 197.24.
- CSL is scheduled to release its next results on February 10, 2027.
Evans and Partners moved its recommendation on CSL to Neutral on November 16 and adjusted its price target to AUD 197.24. MarketScreener carried the MT Newswires report and identified the analyst action as a November 16 event.
Neutral call raises focus on execution
The rating change adds a more cautious view to the investment case as CSL works through its recovery agenda. Investors are weighing the outlook for plasma operations, cost savings and the performance of CSL Behring, CSL Seqirus and CSL Vifor.
MarketScreener lists February 10, 2027, as CSL's next earnings release date. That report is expected to give investors the next scheduled update on operating progress and management's outlook.
CSL stock traded at 115.72 euros on Lang & Schwarz at 10:21 CET on Saturday, November 21.
CSL Limited stock facts
- Company: CSL Limited
- ISIN: AU000000CSL8
- Lang & Schwarz quote: 115.72 euros at 10:21 CET on November 21, 2026
- Analyst action: Evans and Partners moved the recommendation to Neutral
- Price target: AUD 197.24
- Next earnings release: February 10, 2027
Australian equities remain the relevant market context for CSL investors; Current market reports track broader developments.
